Pilar Rivera

Group website

Research Outline

Translational nanomedicine: understanding and engineering the nanomaterial-biological system interface by creating a theranostic tool towards a more personalized medicinal disease management.

 

Research Lines

2020–2023: PID2019-106755RB-I00: 140,000€ MICINN-AEI “Beyond NanoTarg’s technology towards suppression of cancer progression”

2020-2022: 2019 INNOV 00002 [FEDER]: 84,000€ AGAUR “Labeling against product counterfeiting”

2020-2022: TECSPR19-1-0019: 163,726.42€ ACCIÓ “Theranostic nanoplatform for tumor progression”

2019 – 2021: 2018-PROD-00024: 100,000€ (ACCIÓ GenCat) NanoTarg

 

 

Team during 2019-20

PhD students: Paula Zamora Pérez, Weiteng An, Ruixue Xu, Can Xiao, Ting Zhou, Francisco Rodríguez. 

Postdocs: Oihane Fragueiro, Markus Marcincic, Bernat Mir de Simón 

Technicians: Yolanda Tor 

 

Selected publications 

 
  • EP20382172.3 “Treatment and/or diagnosis of a cancer type characterized by expressing a transporter” Pilar Rivera Gil, Rubén Vicente, Ruixue Xu, 2020 
 
  • Muñoz-Ortiz T, Hu J,. Ortgies D H, Shrikhande S, Zamora-Pérez P, Granado M, González-Hedström D, de la Fuente-Fernández M, Villalón AL, Martín Rodríguez E, Aguilar R, Alfonso F, García Solé J, Rivera Gil P, Rivero F, Jaque D (2020) Molecular Imaging of infarcted heart by biofunctionalized Gold Nanoshells. Accepted Advanced Healthcare Materials adhm.202002186.

  • K. Simeonidis, C. Martinez-Boubeta, P. Zamora-Pérez, P. Rivera-Gil, E. Kaprara, E. Kokkinos, M. Mitrakas “Implementing nanoparticles for competitive drinking water purification”. Environmental Chemistry Letters 2019, 17, p.: 705–719.